Of the total ER visits, nearly 70% involved GI issues, 15% of which led to hospitalization, according to a new study.

In a new study, Ozempic - a drug sold to help with obesity and diabetes - is attributed to helping this disease.

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

A decision is expected in the fourth quarter of 2025.

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg oral formulation of Wegovy® ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved for Type-2 diabetes, but ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...